| 1 |
30048718 | Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. | 2018 Oct 14 |
1 |
| 2 |
24223414 | Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. | 2013 |
1 |
| 3 |
19349545 | Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. | 2009 Jun 10 |
1 |
| 4 |
18487550 | Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. | 2008 Oct |
5 |
| 5 |
16442593 | Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. | 2006 Feb |
1 |
| 6 |
15668260 | Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. | 2005 Mar |
1 |
| 7 |
15470213 | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. | 2004 Oct 7 |
1 |
| 8 |
12756087 | Chemotherapy of prostate cancer: present and future. | 2003 Jun |
1 |
| 9 |
12441935 | Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. | 2002 Dec |
2 |
| 10 |
11596021 | Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. | 2001 Oct 15 |
2 |
| 11 |
10751862 | Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. | 2000 May |
2 |